Pulse Biosciences (PLSE) Stock Forecast & Price Target

Pulse Biosciences is attractive fundamentally because its nsPFA platform appears meaningfully differentiated, delivering non-thermal ablation in about five seconds with 100% procedural success at six months, 96.2% at 12 months, and about 90% freedom from AF/AFL/AT at one year in 141 European patients. The technology’s speed and workflow advantages versus microsecond PFA, plus more than 250 issued patents and active pivotal programs, support a durable competitive moat and a credible path to commercialization. Financially, it ended 2Q26 with $101.6M in cash and no debt, while early Vybrance revenue exceeded $800,000 in 1H26, giving it runway to reach major catalysts.

Pulse Biosciences is a high-risk, pre-revenue medtech company whose valuation depends on unproven clinical and regulatory execution, and the excerpts highlight the possibility of pivotal trial delays, disappointing results, and FDA setbacks if the 96% procedural success or 90% freedom-from-arrhythmia benchmarks deteriorate. Its commercialization path is also fragile because it may fail to secure an acceptable partnership against much larger EP incumbents, leaving it with limited sales infrastructure and a likely need for dilutive equity financing. The financial profile underscores this strain: full-year 2025 revenue was only $0.4M, 1H26A revenue was $0.8M, free cash outflow was about $54M in 2025 and ~$33M in 1H26, despite ~$115M in pro-forma gross cash as of 2Q26.